
Pizotifen Malate
CAS No. 5189-11-7
Pizotifen Malate ( —— )
产品货号. M14815 CAS No. 5189-11-7
Pizotifen malate 是一种高选择性 5-HT 受体阻断剂,是一种基于苯并环庚烷的化合物。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
100MG | ¥340 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Pizotifen Malate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Pizotifen malate 是一种高选择性 5-HT 受体阻断剂,是一种基于苯并环庚烷的化合物。
-
产品描述Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.
-
体外实验Pizotifen malate (BC-105 malate)is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site. Pizotifen is an antidepresent 5-HT2A receptor antagonist and has the capacity to inhibit serotonin-enhanced ADP-induced platelet aggregation.
-
体内实验The weights of the fetuses are significantly reduced by all administered doses of Pipethiadene and Pizotifen malate (BC-105 malate) ; the weights of the placentas are significantly reduced after 0.6 and 1.2 mg/kg Pipethiadene and only after the middle dose of Pizotifen malate. The means of the implantations, live, dead fetuses, resorptions and the occurrence of external, skeletal and visceral anomalies do not differ from the control group. The number of chromosome aberrations in the bone marrow cells of treated mice does not differ significantly from the negative control group. The micronucleus test reveals no elevation in the frequency of micronuclei as compared to the control group. After the two higher doses of both Pipethiadene and Pizotifen maleate, the mitotic indices are lower than in the control group.
-
同义词——
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体5-HT
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number5189-11-7
-
分子量429.53
-
分子式C19H21NS·C4H6O5
-
纯度>98% (HPLC)
-
溶解度DMSO: 21 mg/mL (48.89 mM)
-
SMILESOC(=O)C=CC(O)=O.CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Margarit MV, et al. Drug Dev Ind Pharm. 2001 Jul;27(6):517-22.